Locus Cell Co

Locus Cell Co CROIC

The Cash Return on Invested Capital (CROIC) of Locus Cell Co (6891.TWO) as of Oct 16, 2026 is -30.81 %. In the previous year, Cash Return on Invested Capital (CROIC) was -8.52 % — a change of 261.71% (lower).

CROIC

-30.81 %

YoY

261.71%

Last updated:

Cash Return on Invested Capital (CROIC) of Locus Cell Co is 2024 -30.81 % . Cash Return on Invested Capital (CROIC) of Locus Cell Co was 2023 -8.52 % . It decreases by 261.71% lower compared to the previous year.

The Locus Cell Co CROIC history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

CROIC
Date
CROIC
Jan 1, 2020
0.00 TWD
Jan 1, 2021
-1.49 TWD
Jan 1, 2022
-3.12 TWD
Jan 1, 2023
-8.52 TWD
Jan 1, 2024
-30.81 TWD
The Locus Cell Co CROIC history
YEARCROICYoY
-30.81 %+261.71%
-8.52 %+172.90%
-3.12 %+108.81%
-1.49 %—
0.00—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Locus Cell Co Stock analysis

What does Locus Cell Co do? Locus Cell Co Ltd is a company based in Taipei, Taiwan, operating within the Health Care sector, specifically in the Life Sciences Tools & Services industry. The company has 32 employees and went public on April 28, 2022. Its primary business involves the entrusted development and manufacturing of cell therapy-related products. Locus Cell Co Ltd utilizes a pilot facility compliant with Pharmaceutical Inspection Convention and Pharmaceutical Inspection Co-operation Scheme (PIC/S) good manufacturing practices (GMP). The company provides services including process development and scale-up for cell therapy products, analytical method development and validation, clinical GMP manufacturing for trials, and stability testing. It is anticipated to offer services for various cell therapy applications, such as tissue engineering, CAR-T, induced pluripotent stem cells (iPSCs), and mesenchymal stem cells (MSCs). The company's website is http://www.locus-cell.com/. Locus Cell Co Ltd focuses on contract development and manufacturing organization (CDMO) services for cell therapy products, aiming to support the advancement of innovative therapies through its specialized GMP-compliant facility and technical expertise in cell therapy processes. Locus Cell Co is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Locus Cell Co stock

Cash Return on Invested Capital (CROIC) of Locus Cell Co is -30.81 % in 2024.

Cash Return on Invested Capital (CROIC) of Locus Cell Co changed from -8.52 % to -30.81 %, representing a 261.71% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of Cash Return on Invested Capital (CROIC) Locus Cell Co since 2006 – with annual values, charts, and detailed analysis.

CROIC measures the cash return generated on invested capital. Unlike ROIC, it uses free cash flow instead of accounting earnings, providing a purer profitability measure.

A 'good' varies by industry and company stage. On Eulerpool, you can compare Cash Return on Invested Capital (CROIC)'s Locus Cell Co with sector peers and the industry average to assess whether it is attractive.

To evaluate Cash Return on Invested Capital (CROIC)'s, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for Cash Return on Invested Capital (CROIC).

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Profitability — Locus Cell Co

All Key Metrics — Locus Cell Co